Chest Physiotherapy and Airway Clearance Devices
Customize your policy alerts
Sign up for Aetna Policy 0067 alerts
Get alerted when Policy 0067 changes without checking for updates manually.
Monitor payer policy activity
Governs medical necessity and coverage of chest physiotherapy and airway clearance devices (DME) for Aetna members, including indications, investigational devices, and applicable billing codes; affects providers prescribing or supplying these services and equipment.
No material clinical or coverage changes in this revision.
Coverage Criteria for Chest Physiotherapy and Airway Clearance Devices
Chest physiotherapy (therapist-delivered)
Covered when specific conditions and context are met:
Chest physiotherapy by a respiratory therapist is not considered medically necessary for persons whose pulmonary condition is stable, as chest physiotherapy can be competently administered at home by a family member or caregiver.
Covered airway clearance DME and indications
Airway clearance devices (DME) are covered when ALL of the following apply for the specified device classes:
List of qualifying neuromuscular diagnoses is enumerated in policy (see policy text).
Examples of neuromuscular diagnoses include amyotrophic lateral sclerosis, congenital myopathies, inclusion body myositis, muscular dystrophy, myasthenia gravis, poliomyelitis, progressive bulbar palsy, spinal muscular atrophy, and high spinal cord injury with quadriplegia.
Evidence summaries and situational considerations
Summary of clinical evidence and contexts where devices may be considered
Trial enrolled 107 subjects across 12 centers; results favored PEP over HFCWO for pulmonary exacerbations.
Study included 23 patients (26 admissions); recommended further randomized study.
IPV evidence described as limited; routine use not supported without specific justification.
PEP trials showed improvements in some lung function and exacerbation outcomes compared with other techniques.
Consensus reports support physiologic benefit but call out lack of morbidity/mortality data.
MI-E / Cough augmentation
Summary of clinical findings and contexts where devices were studied
Overall evidence quality rated low/very low with limited sample sizes and risk of bias; adverse events reported but few serious events.
Other modalities (CHFO, nHFOV, HFNC, HFCWO)
Findings from studies of other airway clearance or respiratory support modalities
Feasibility/safety data are preliminary and not definitive for efficacy.
Trials reported mixed but promising physiologic/clinical signals; routine adoption requires further evidence.
Evidence heterogeneous across patient populations; further study needed for definitive guidance.
Findings limited; larger studies needed to clarify clinical benefits.
Evidence-based coverage considerations
Evidence summary and implied coverage considerations based on clinical studies and device-specific findings
Lack of randomized data and potential confounding limit certainty; absence of demonstrated improvement in key longer-term outcomes may influence coverage decisions.
Clinical trials are ongoing; lack of robust outcomes data may justify prior authorization or investigational status for some indications.
Consider conservative/stepwise approaches (e.g., respiratory muscle training, PEP) before device coverage for dyspnea in COPD.
Insufficient evidence for routine coverage; further trials required.
Recommend prior authorization and documentation of prior therapies and indication when considering high-cost modalities.
Requests for high-frequency chest compression systems (HFCWO) when the member does not meet the policy's specified medical necessity criteria (for example, diagnoses such as alpha-1 antitrypsin deficiency, anoxic brain injury, cerebral palsy, childhood atelectasis, interstitial lung disease, scoliosis, Zellweger syndrome, and other listed conditions) may be considered experimental/investigational due to insufficient evidence of effectiveness and are subject to denial. The policy explicitly lists HFCWO for "other indications in members who do not meet medical necessity criteria" for which effectiveness has not been established.
Randomized evidence in cystic fibrosis does not support HFCWO as the primary airway clearance modality compared with PEP mask therapy; a multicenter randomized trial reported fewer pulmonary exacerbations and longer time to first exacerbation with PEP than with HFCWO, and the authors concluded the results did not support HFCWO as primary therapy in CF. Similarly, intrapulmonary percussive ventilation (IPV) and other adjunctive therapies have limited and mixed evidence and are not supported as routine primary treatments without specific justification.
No explicit coverage exclusions are stated in this portion of the document segment beyond the investigational/insufficient-evidence listings; the policy's exclusions and investigational device statements are provided elsewhere in the bulletin.
The Volara System (OLE) and related MetaNeb/OLE-type devices lack sufficient evidence of improved health outcomes outside populations studied (for example, high‑risk postsurgical cohorts or research protocols). Use of these systems for indications without supporting outcomes data may be considered investigational.
The policy's reference lists do not themselves specify coverage exclusions; they serve to document the literature cited in the bulletin rather than to define coverage determinations.
Clinical Policy Bulletins are developed to assist in administering plan benefits and do not constitute offers of coverage or medical advice. These documents provide a general, partial description of plan benefits and do not replace program-specific contract language; treating providers remain responsible for medical decisions.
Chest physiotherapy provided by a respiratory therapist is considered medically necessary for initial prescription and when the member's pulmonary condition is unstable. However, the policy specifies that respiratory therapist–delivered chest physiotherapy is not considered medically necessary for persons with a stable pulmonary condition because competent chest physiotherapy can be administered at home by a family member or caregiver.
Routine or automatic use of intrapulmonary percussive ventilation (IPV) and similar adjunctive therapies in hospitalized or ventilated patients is not supported by sufficient scientific evidence; guideline panels have considered IPV but did not recommend it because of inadequate data, so routine coverage without specific justification is not supported.
While physiologic and small clinical studies report improvements in cough mechanics and peak cough flows with some nonpharmacologic protussive therapies, the document notes that clinical studies demonstrating improvements in patient morbidity and mortality are generally lacking, limiting conclusions about the impact of many device‑based airway clearance interventions on major health outcomes.
A randomized, double‑blind, sham‑controlled trial of combined high‑frequency airway oscillation with inspiratory muscle training in COPD did not show superiority over sham for the primary dyspnea outcome (CRQ‑D), indicating no demonstrated dyspnea benefit in that trial.
Portions of the bulletin labeled as references contain citation listings only and serve as bibliographic support for the policy; they do not by themselves state clinical positions, coverage criteria, or medical necessity determinations.
There are no explicit 'not medically necessary' statements contained in the referenced administrative/additional‑information chunks; the Additional Information section reiterates that the Clinical Policy Bulletin is informational and not a substitute for specific plan contract terms.
Billing Codes and Coding Guidance
| 94667 | Manipulation chest wall, such as cupping, percussing and vibration to facilitate lung function; initial demonstration and/or evaluation or subsequent. |
| 94668 | Manipulation chest wall, such as cupping, percussing and vibration to facilitate lung function; initial demonstration and/or evaluation or subsequent. |
| 94669 | Mechanical chest wall oscillation to facilitate lung function, per session. |
| 97124 | Therapeutic procedure, one or more areas, each 15 minutes; massage, including effleurage, petrissage and/or tapotement (stroking, compression, percussion). |
| G0237 | Therapeutic procedures to increase strength or endurance of respiratory muscles, face-to-face, one-on-one, each 15 minutes (includes monitoring). |
| G0238 | Therapeutic procedures to improve respiratory function, other than described by G0237, one-on-one, face-to-face, per 15 minutes (including monitoring). |
| S8185 | Flutter device. |
| E0483 | High frequency chest wall oscillation air-pulse generator system, (includes hoses and vest), each. |
| A7025 | High frequency chest wall oscillation system vest, replacement for use with patient owned equipment, each. |
| A7026 | High frequency chest wall oscillation system hose, replacement for use with patient owned equipment, each. |
| E0481 | Intrapulmonary percussive ventilation system and related accessories. |
| E84.0 - E84.9 | Cystic fibrosis. |
| J47.0 - J47.9 | Bronchiectasis. |
| J41.0 - J42 | Chronic bronchitis. |
| J45.20 - J45.998 | Asthma. |
| G12.20 - G12.29 | Motor neuron disease. |
| G70.00 - G73.7 | Diseases of myoneural junction and muscle. |
| G82.20 - G82.54 | Paraplegia and quadriplegia. |
| Z94.2 | Lung transplant status. |
| E71.510 | Zellweger syndrome. |
| F84.2 | Rett's syndrome. |
| G25.82 | Stiff-Man Syndrome. |
| J96.00 - J96.02 | Acute respiratory failure. |
| J44.0 - J44.9 | Chronic obstructive pulmonary disease. |
| No codes listed |
| none listed | No CPT/HCPCS/ICD codes are provided in this document segment. |
| K121170 | FDA 510(k) Premarket Notification (RespIn11 Model Powered Precursory) |
| No codes listed |
Provider Requirements, Prior Authorization & Documentation
Prior authorization required for durable airway‑clearance DME
Prior authorization is required for durable airway clearance equipment (HFCWO systems, mechanical percussors, PEP devices, Flutter/Acapella, mechanical insufflation-exsufflation) and associated HCPCS/CPT codes; coverage is contingent on meeting the policy's clinical criteria.
Recommend prior authorization for low‑evidence devices
Devices and therapies with limited or mixed evidence (for example, HFCWO for some indications, IPV, mechanical insufflation‑exsufflation) may require prior authorization with documentation of clinical indication, prior therapies tried, and clinical rationale.
- Policy notes lack of high‑level evidence for IPV and mixed/limited data for HFCWO outside CF.
- Documentation should justify use given limited supporting trials and guideline statements.
No specific PA rules specified in this segment
The document segment focuses on clinical evidence and device effectiveness and does not specify concrete prior authorization rules or programmatic PA procedures within these chunks.
- Clinical content emphasizes efficacy/safety; billing or explicit PA directives are not provided here.
PA may be required for OLE/MetaNeb given limited evidence
Prior authorization may be required when requesting Oscillation & Lung Expansion (OLE) systems such as Volara or MetaNeb because evidence demonstrating improved health outcomes is limited; requests should include clinical indication and supporting trial or risk‑factor data.
- Volara/OLE evidence is limited and Huynh et al reported nonrandomized cohort comparisons; stage II OLE subjects were older with higher ASA but showed adjusted PPC reduction—documentation of patient risk factors and procedure type is relevant.
Prior authorization not addressed in reference lists
The reference lists and citation sections do not contain prior authorization rules or authorization requirements for providers.
- References section supplies citations only and does not provide PA directives.
Policy history does not specify PA requirements
Policy history and administrative notes are provided but do not specify concrete prior authorization requirements or list affected billing codes in these administrative chunks.
- Policy history shows last review and effective dates but contains no PA instructions.
Try simpler/manual therapies before HFCWO for non‑CF indications
For non‑CF indications, the policy indicates considering simpler or less expensive devices (e.g., Flutter, Acapella) or manual chest physiotherapy before approving HFCWO; HFCWO may be considered where manual therapy is unavailable or has failed.
- Authors note absence of adequate studies comparing HFCWO to less expensive devices (Flutter/Acapella) and recommend considering alternatives.
- HFCWO can be used in place of manual CPT when manual therapy is unavailable.
Step through PEP/Flutter/Acapella before HFCWO
When applicable, established airway‑clearance methods such as PEP (including Flutter/Acapella) should be attempted prior to higher‑cost modalities like HFCWO, supported by randomized evidence favoring PEP over HFCWO in CF.
- McIlwaine et al (2013) randomized CF patients and found fewer pulmonary exacerbations with PEP versus HFCWO.
No explicit step‑therapy algorithm provided
The authors state that long‑term comparative data are lacking; explicit step‑therapy protocols are not specified in this document and further research is needed to evaluate relative success of airway‑clearance methods.
- Policy text notes the need for long‑term comparisons and appropriate outcome measures before defining step therapy.
Conservative first‑line approach suggested before device therapy
Randomized trial evidence (e.g., HFAO + IMT vs sham in COPD) found no difference in primary dyspnea outcome, supporting a conservative, stepwise approach (e.g., respiratory muscle training or simpler therapies) before device therapy.
- Daynes et al (2022) observed no statistical difference in CRQ‑D between HFAO and sham, suggesting conservative first‑line options may be reasonable.
Step therapy requirements not discussed in references
Reference entries in this portion do not discuss step‑therapy programmatic requirements or impose prior sequencing of therapies.
- References supply background literature but not coverage sequencing rules.
No step‑therapy rules specified in policy history
The administrative and policy‑history chunks do not specify any step‑therapy requirements or mandated trial sequences for airway clearance devices.
- Policy history and additional information emphasize that CPBs do not substitute for program contract language.
Document clinical indication and prior treatments to justify DME
Documentation submitted for device coverage must demonstrate the specific clinical indication (e.g., cystic fibrosis, bronchiectasis confirmed by CT with daily productive cough ≥6 months or >2 antibiotic‑requiring exacerbations/year, listed neuromuscular diagnoses, lung transplant within 6 months intolerant of CPT) and prior failure of standard treatments when applicable.
- Policy enumerates qualifying conditions and broniectasis symptom/exacerbation thresholds for HFCWO coverage.
Pediatric HFCWO requires radiographic and treatment‑failure documentation
For pediatric or infant use of HFCWO to treat recalcitrant atelectasis, documentation should include radiographic evidence of atelectasis not responding to mucolytic therapy and conventional chest physiotherapy, device settings used, and tolerability.
- Retrospective series reported radiographic confirmation and prior failure of mucolytic therapy and CPT; described tolerated device settings (e.g., 8 Hz × 10 min then 10 Hz × 10 min at pressure 15).
Include trial characteristics and adverse‑event monitoring in supporting documentation
Based on the evidence summaries, providers should include trial characteristics (study population, interventions, outcomes) and any adverse events or monitoring when documenting device use, as these factors were assessed in systematic reviews and primary studies.
- Cochrane‑style reviews assessed RCTs and nonrandomized studies and reported risks of bias and harms; analogous documentation is expected in clinical practice.
Provide OLE/Volara supporting trial‑style documentation (demographics, ASA, procedure type)
For OLE/Volara requests, provide supporting documentation analogous to published studies (patient demographics, ASA score, procedure type, and baseline PPC risk) to justify use in high‑risk postsurgical patients.
- Huynh et al reported adjusted analyses including age, ASA score, and operation time when assessing OLE impact on postoperative pulmonary complications.
References do not specify provider documentation requirements
The references section does not itself provide concrete provider documentation checklists or authorization forms; it is a bibliography of supporting literature.
- Reference lists are for evidence support and do not replace required clinical documentation for authorization.
Providers retain responsibility for treatment decisions despite CPB guidance
Providers remain responsible for treatment decisions; the Clinical Policy Bulletin is intended to assist benefit administration and does not substitute for medical judgment or program‑specific contract rules.
- Additional Information notes CPBs do not constitute offers of coverage or medical advice.
Denial risk for devices listed as experimental/investigational
Requests for devices or interventions listed as experimental/investigational (for example, IPV, Volara OLE, Simeox, and HFCWO when used for indications not meeting medical‑necessity criteria) are subject to denial.
- Policy explicitly lists IPV, Volara OLE, Simeox, and HFCWO for non‑qualifying indications as experimental/investigational and not covered.
Evidence gaps create coverage/denial risk
Use of devices with insufficient evidence (for example, IPV or HFCWO as primary therapy in CF) or interventions not supported by randomized data may result in noncoverage or denial.
- McIlwaine et al (2013) found PEP superior to HFCWO as primary therapy in CF; IPV is noted as lacking sufficient evidence and was considered but not recommended by guideline panels.
No additional provider actions provided in this segment
The document does not supply additional provider‑action content in this segment beyond the items already summarized.
Volara (OLE) lack of evidence may lead to denial
Lack of evidence supporting effectiveness of the Volara System in improving patient‑centered outcomes may trigger medical‑necessity denials for coverage of that device unless clear supporting clinical justification is provided.
- Volara System OLE is described as lacking evidence to support improved health outcomes.
No authorization or denial rules in reference sections
The reference sections in these chunks do not state authorization requirements or specific denial triggers for providers.
- Reference lists are cited for evidence and do not include PA or denial procedural content.
No explicit denial triggers listed in these administrative chunks
These document chunks do not list explicit denial triggers; denials are tied to devices or uses designated as experimental/investigational or lacking sufficient evidence.
- Administrative material and additional information do not enumerate denial triggers beyond policy statements.
Background and Purpose
Chest physiotherapy and airway clearance techniques are intended to mobilize and remove pulmonary secretions to reduce airway obstruction, prevent or treat atelectasis, and decrease the risk of infection. Standard manual chest physiotherapy typically includes percussion, vibration, postural drainage and assisted coughing and is often delivered 1–3 times daily; device‑based therapies aim to permit independent use or substitute for manual therapy in select indications.
Device and Therapy Definitions
Policy History and Review Dates
Policy history and administrative review information are provided in the bulletin's Additional Information section; these administrative notes reinforce that the Clinical Policy Bulletin is intended to guide benefit administration but is not a contract and does not replace provider clinical judgment.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.